Cell therapy · developed by Lisata Therapeutics
CLBS12 is an intramuscular transfusion product studied in patients with critical limb ischemia, thromboangiitis obliterans (Buerger disease) and atherosclerosis obliterans.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02501018 | Phase 2 | Critical Limb Ischemia | Completed | LSTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atherosclerosis ObliteransBuerger DiseaseCritical Limb IschemiaThromboangiitis Obliterans
Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.
See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LSTA catalysts and pipeline →